Viatris Inc. Stock
€10.40
Your prediction
Viatris Inc. Stock
Pros and Cons of Viatris Inc. in the next few years
Pros
Cons
Performance of Viatris Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Viatris Inc. | -1.090% | 1.692% | -3.444% | 1.791% | 7.824% | -16.215% | -38.895% |
Hikma Pharmaceuticals | - | 0.000% | 10.092% | 0.000% | 17.647% | -19.463% | 9.339% |
Indivior plc | -0.900% | -2.609% | 17.277% | -48.387% | -18.958% | 0.269% | 233.532% |
Opko Health Inc. | 1.050% | 4.120% | 2.669% | -8.304% | -0.617% | -52.608% | -21.648% |
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Viatris (VTRS) reveals a multifaceted picture, one that reflects both opportunities and challenges within the pharmaceutical industry. Despite facing headwinds in recent years, including a decline in both revenue and earnings, Viatris retains a significant market presence backed by substantial assets and a diversified product line. The current financial metrics indicate a company that is navigating through a transitional phase, compelled to adapt and respond to various market pressures while also maintaining a clear focus on delivering value to its stakeholders.
Strong Asset Base: Viatris possesses a solid balance sheet with total assets amounting to approximately $47.7 billion in 2023. The company's intangible assets, which primarily include patents and proprietary technologies, totaled about $19.2 billion. This asset base underscores the potential for leverage in growth strategies and innovation in its pharmaceutical offerings.
Free Cash Flow Generation: The company generated a robust free cash flow of about $2.3 billion in the latest fiscal year. This is a positive indicator of Viatris's ability to fund its operations, reinvest in its business, and provide returns to shareholders through dividends, which currently yield just under 4%.
Comments
News
![Why Viatris Stock Is Jumping Today: https://g.foolcdn.com/editorial/images/786497/scientists-smiling-and-shaking-hands.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkh5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1b1d9527f2658068f205879fefe723c3b490bdd5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-smiling-and-shaking-hands.jpg?locale=us)
Why Viatris Stock Is Jumping Today
Shares of Viatris (NASDAQ: VTRS) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the global healthcare company
![Is Viatris a Great Dividend Stock or Just a Value Trap?: https://g.foolcdn.com/editorial/images/768795/a-couple-reviewing-a-document-at-home.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEZWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a4c290c7a54a7f52f02a23352b5eb262c496c574/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-document-at-home.jpg?locale=us)
Is Viatris a Great Dividend Stock or Just a Value Trap?
Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around